Atractylenolide III, a natural product isolated and purified from the rhizome of Atractylodes macrocephala Koidz., may have therapeutic potential in treating homocysteine-mediated cognitive impairment and neuronal injury, and is a potential candidate for treatment of human lung carcinoma by inducing the release of cytochrome c, upregulating the expression of bax and translocating apoptosis-inducing factor.
Atractylenolide III, also known as ICodonolactone, constitutes the primary active compound of the Atractylodes rhizome and exhibits the capability to induce apoptosis in lung cancer cells. It is recognized for its oral efficacy as a gastroprotective agent .
体内研究
Atractylenolide III, administered orally at doses of 5 and 10 mg/kg, demonstrates gastroprotective effects and reduces gastric ulcers induced by 70% ethanol in rats by up to 70%[2].
Atractylenolide III, when administered at 30 mg/kg through oral gavage for either 14 or 28 days, alleviates depressive- and anxiogenic-like behaviors in rat models of depression. This effect is observed in models induced by lipopolysaccharide (LPS) and chronic unpredictable mild stress (CUMS)[5].
体外研究
Atractylenolide III, at concentrations ranging from 1 to 100 μM over 48 hours, induces apoptosis in A549 cells, as evidenced by the activation of caspase-3 and caspase-9 and the cleavage of PARP[1].
Atractylenolide III, in concentrations between 1 and 100 μM over a period of 72 hours, inhibits proliferation and angiogenesis, as indicated by tube formation, in Human Umbilical Vein Endothelial Cells (HUVECs)[1].
Atractylenolide III, at concentrations of 1-100 μM, inhibits the production of proinflammatory cytokines (IL-6, IL-1β, TNF-α, and IL-8) induced by thymic stromal lymphopoietin (TSLP) in HMC-1 cells[4].
搜索
